CHMP Nod For Ipsen's Mainstay Cancer Drug Cabometyx In First-Line RCC

 
• By Lucie Ellis-Taitt
  
Recommended
CHMP recommends approval of Ipsen's Cabometyx in first-line RCC
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Anticancer

More from Therapy Areas